UroGen Pharma (URGN) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- US stock futures mixed as Apple slides, midterms loom
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($0.47), $0.03 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $50.96 million versus the consensus estimate of $44.46 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xometry, Inc. (XMTR) Tops Q3 EPS by 9c ; Offers Guidance
- Strata Critical Medical, Inc. (SRTA) Misses Q3 EPS by 8c
- Nuveen Churchill Direct Lending Corp. (NCDL) Misses Q3 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
